ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Cellular & Molecular Immunology is a prestigious peer-reviewed journal published by the CHIN SOCIETY IMMUNOLOGY. As a leading journal in the fields of immunology and infectious diseases, it proudly holds a Q1 designation across multiple categories, including Immunology, Allergy, and Medicine (Miscellaneous), reflecting its commitment to excellence and impactful research. With an ISSN of 1672-7681 and an E-ISSN of 2042-0226, the journal has been essential reading since its inception in 2004, continuously gathering insights from cutting-edge studies. It ranks impressively within Scopus, with positions in the 7th, 8th, and 9th percentile in relevant categories, establishing it as a cornerstone for researchers, clinicians, and students alike. The journal offers an extensive range of original research articles, reviews, and clinical studies, ensuring that readers stay at the forefront of immunological discovery. Whether you are interested in basic immunology, infectious diseases, or evolving therapies, Cellular & Molecular Immunology serves as an invaluable resource for advancing your knowledge and engagement in this dynamic field.

Journal of Immunotoxicology, published by Taylor & Francis Ltd, is at the forefront of research in the intersecting fields of immunology and toxicology. With an annual impact factor that reflects its growing influence, this Open Access journal has been essential for disseminating valuable knowledge since its inception in 2004. The journal welcomes novel research articles, reviews, and commentary that explore the effects of xenobiotics on the immune system, contributing to a deeper understanding of immunotoxicological mechanisms and implications for human health. As a recognized platform, it has achieved commendable rankings in Scopus, positioning it within Q3 in Immunology and Q2 in Toxicology categories as of 2023. This ensures that the journal remains a critical resource for researchers, professionals, and students seeking to advance their knowledge and contribute to the evolving landscape of immunotoxicology. With an Open Access model since 2017, it maximizes accessibility and reaches a global audience, supporting the collaborative efforts needed to address contemporary challenges in health and safety.

CELLULAR IMMUNOLOGY is a prestigious journal published by Academic Press Inc. Elsevier Science, dedicated to advancing the field of immunology. Established in 1970 and converging ongoing research up to 2024, this journal has carved out a significant niche within the academic community, boasting a notable Q2 ranking in the Immunology category and holding a respectable 67th percentile ranking within Scopus for its contributions to the disciplines of Immunology and Microbiology. The journal serves as a vital platform for disseminating high-quality research, reviews, and methodologies that elucidate the intricacies of cellular immune responses, thereby benefiting researchers, professionals, and students alike. Although it does not offer open access, the journal's impact is evidenced by its comprehensive coverage of pioneering studies and ongoing developments in the immunological sciences, positioning it as an essential resource for those seeking to deepen their understanding and engage with the latest findings in cellular immunology.

ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, published by DE GRUYTER POLAND SP Z O O, stands as a pivotal journal in the field of immunology, contributing significantly to the advancement of knowledge and therapy in this crucial area of medicine since its inception in 1954. With an ISSN of 0004-069X and an E-ISSN of 1661-4917, the journal operates out of Switzerland, catering to an international audience of researchers, practitioners, and students. As reflected in its Scopus rankings, the journal is positioned within the third quartile in both Immunology and Allergy (Q3) and holds a commendable second quartile in Medicine (miscellaneous) (Q2), indicating its respectable influence within the academic community. The journal publishes original research, reviews, and clinical studies, offering a platform for exploring cutting-edge developments in immunological therapies and experimental methods. Although not currently an open-access journal, it continues to thrive as a valuable resource, reflecting a commitment to disseminating high-quality research and fostering academic discourse in the field. Researchers and professionals alike will find ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS an essential reference source for the latest advancements in immunological research and clinical applications.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Journal of Inflammation-London, published by BMC, is a premier open access journal dedicated to advancing the understanding of inflammation, a critical process underlying numerous diseases including autoimmune disorders, cancer, and cardiovascular conditions. With its inception in 2004, the journal has consistently delivered high-quality research that bridges basic science and clinical applications, maintaining a significant place in the academic community. It holds impressive rankings within the Q2 category for both Cell Biology and Clinical Biochemistry, reflecting its impactful contributions to these fields, where it ranks in the 73rd and 64th percentiles respectively. The journal is committed to open access principles, ensuring that all published articles are freely available to researchers, practitioners, and the global community, thereby fostering collaboration and innovation. Located in the United Kingdom, the journal continues to attract submissions from prominent researchers and institutions worldwide, solidifying its status as an essential resource for the latest developments in inflammation research.

Mucosal Immunology, published by Elsevier Science Inc, is a leading journal dedicated to advancing the field of immunology with a particular focus on mucosal immunity. Since its inception in 2008, the journal has established itself as a premier source of cutting-edge research, evidenced by its impressive Q1 ranking in both Immunology and Allergy for 2023, and its notable positions within the top ranks of Scopus (Rank #21/233 in Immunology and Allergy and Rank #24/236 in Immunology and Microbiology). The journal serves as a vital resource for researchers, professionals, and students aiming to explore the complexities of mucosal immune responses and their implications in health and disease. While it operates under a subscription model, Mucosal Immunology is committed to disseminating quality research globally and enhancing collaborative efforts within the scientific community. Explore the latest findings and connect with influential scholarship in this rapidly evolving field.

IMUNOLOGY AND CELL BIOLOGY, published by Wiley, serves as a prominent platform for disseminating cutting-edge research in the fields of immunology and cell biology. With an ISSN of 0818-9641 and an E-ISSN of 1440-1711, this journal has established itself since its inception in 1987, demonstrating a commitment to advancing knowledge in its disciplines through high-quality articles. Renowned for its rigorous peer-review process, it holds a Q2 quartile ranking in both immunology and cell biology categories as of 2023, showing its competitive stature in these fields. IMUNOLOGY AND CELL BIOLOGY is indexed among the elite journals worldwide, with impressive Scopus rankings, including a rank of #75/233 in Immunology and Allergy. The journal’s comprehensive scope ensures that it caters to an audience of researchers, professionals, and students who are dedicated to exploring the intricate mechanisms of immune responses and cellular interactions. Although it does not operate under an open access model, its subscription-based content remains invaluable for those seeking to broaden their understanding of immunology and cell biology. By providing a forum for significant scientific dialogue, IMUNOLOGY AND CELL BIOLOGY continues to shape the future of research in these vital areas.

Immunopharmacology and Immunotoxicology, published by Taylor & Francis Ltd, is a distinguished academic journal with a focus on the interrelation between pharmacology, immunology, and toxicology. Established in 1978, the journal serves as a vital platform for the dissemination of cutting-edge research aimed at enhancing the understanding of immunologically mediated drug responses and toxic effects. The journal encompasses a broad scope of topics relevant to the fields of immunology, pharmacology, and toxicology, offering insights that are pivotal for both academia and the pharmaceutical industry. With a commendable 2023 impact factor and ranking in Q3 in Immunology and Q2 in both Pharmacology and Toxicology, it holds a respected position within its categories, making it a valuable resource for researchers, professionals, and students seeking to stay abreast of the latest developments in the field. The journal is accessible through traditional subscription models and encourages submissions that bring forth innovative findings that might influence therapeutic strategies and public health.